ImmuPharma plc Corporate Presentation 2020 | Peptide Pipeline

ImmuPharma plc is a London-headquartered biopharmaceutical company listed on UK AIM and Euronext, developing innovative peptide products across autoimmunity, metabolism, anti-infective, and oncology. The company's lead program Lupuzor® (forigerimod) targets lupus and CIDP, with potential launches targeted from 2022-2023 and a US partner announced in Q4 2019.